NayTy personal page - To The Moon

NayTy

No personal profile

13Follow

0Followers

0Topic

0Badge

06-12

See

Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4183047379947902","uuid":"4183047379947902","gmtCreate":1719944238280,"gmtModify":1719946148273,"name":"NayTy","pinyin":"nayty","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.05","exceedPercentage":"80.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.05","exceedPercentage":"93.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":10,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":574294825594880,"gmtCreate":1781217056359,"gmtModify":1781225490787,"author":{"id":"4183047379947902","authorId":"4183047379947902","name":"NayTy","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4183047379947902","idStr":"4183047379947902"},"themes":[],"title":"","htmlText":"See","listText":"See","text":"See","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/574294825594880","repostId":"2642283463","repostType":2,"repost":{"id":"2642283463","kind":"highlight","weMediaInfo":{"introduction":"路透中文","home_visible":1,"media_name":"路透中文","id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1781172061,"share":"https://ttm.financial/m/news/2642283463?lang=en_US&edition=fundamental","pubTime":"2026-06-11 18:01","market":"us","language":"zh","title":"Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2642283463","media":"路透中文","summary":"福利咨询公司美世进行的另一项调查显示，5%的大型雇主计划在2027年停止为这些药物提供报销。健康商业集团的数据显示，2026年67%的大型雇主为GLP-1药物提供报销。多位行业专家指出，与其他治疗方案相比，雇主发现患者长期使用GLP-1类药物的情况增多，且符合用药条件的人群规模更大。怡安表示，该公司同样预计明年GLP-1的保险覆盖范围将缩减。","content":"<p><html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises</title></head><body>Amina Niasse</p><p><span>ReutersNEW YORK June 11</span><span>-</span>As more people use the drugs, some employers plan to eliminate insurance coverage for GLP-1 diet pills in 2027, which offsets Novo Nordisk's (<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>)<span>NOVOb.CO</span>Wegovy and<a href=\"https://laohu8.com/S/LLY\">Lilly</a>(Eli Lilly)<span>LLY.N</span>Some of the savings from Zepbound and Foundayo due to price cuts.</p><p>According to Business Group on Health, a large employer policy research Group, about 10% of employers who currently provide coverage for GLP-1 drugs for weight loss say they plan to eliminate reimbursement for the drug in 2027.</p><p>Another survey conducted by benefits consulting firm Mercer showed that 5% of large employers, which the agency defines as businesses with more than 500 employees, plan to stop offering reimbursements for these drugs in 2027.</p><p>Mercer noted that 44% of businesses with more than 500 employees offer reimbursement for such drugs to people with obesity. Data from the Health Business Group shows that 67% of large employers offered reimbursement for GLP-1 drugs in 2026.</p><p>Reuters was the first to report this month that health insurer Cigna (<span>CI.N</span>) has ceased to reimburse employees for weight loss treatment expenses since July ((<span>link</span>)), and said that employees can purchase these drugs through other channels on their own.</p><p>New weight-loss tablets and injections from Novo and Lilly can now be purchased at a discounted price through the pharmaceutical company's official website, driven by an agreement with TrumpRx.gov, a Trump administration website.</p><p>Novo Nordisk launched its Wegovy diet pill in January, and Eli Lilly began selling its Foundayo diet pill in April, both starting at about $149 a month.</p><p>Many employers remain concerned that they won't get the same savings in agreements with pharmacy benefit managers, industry middlemen who negotiate drug prices for large businesses and health plans, as customers who buy outright and pay in cash, said Lauren Remspecher, director of the Health Purchasing Business Group.</p><p>\"One of the advantages of increased transparency in direct-to-consumer sales, as well as some government negotiated pricing, is that employers can now clearly see how much they are overpaying and where there is room for improvement,\" Remspecher said.</p><p>Oral drugs drive demand growth</p><p>Demand for these drugs has increased this year due to the oral launch, attracting patients who have never tried GLP-1 drugs before, which has led to high employer costs, according to five industry experts.</p><p>Many industry experts pointed out that compared with other treatment options, employers have found that patients have increased their long-term use of GLP-1 drugs, and the number of people eligible for medication is larger.</p><p>Studies show that the weight loss effects of Foundayo and Wegovy are 11% and 14%, respectively. Although they are lower than injectable drugs, they are more favored for patients who are afraid of injections.</p><p>\"Even though we're seeing a decrease in unit prices, the patient population continues to grow,\" said Luis Zollo, head of pharmacy practice at medical consulting firm Segal.</p><p>Aon, a welfare consultancy, has observed that injectable users are switching to oral versions, while patients who are new to GLP-1 also tend to opt for oral medications. Aon said it likewise expects insurance coverage for GLP-1 to shrink next year.</p><p><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Dan Mendelssohn, chief executive of Morgan Health, its Health care arm, said oral drugs are expected to reduce the cost of a single treatment this year.</p><p>\"But the market will grow every year,\" he said, \"and more and more people will take these drugs, so overall, this remains a major cost driver for employers.\"</p><p>(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. Reuters does not guarantee the accuracy of the automated translated text because the automated translation may be incorrect or fail to include the required context, and provides automated translation only for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-06-11 18:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises</title></head><body>Amina Niasse</p><p><span>ReutersNEW YORK June 11</span><span>-</span>As more people use the drugs, some employers plan to eliminate insurance coverage for GLP-1 diet pills in 2027, which offsets Novo Nordisk's (<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>)<span>NOVOb.CO</span>Wegovy and<a href=\"https://laohu8.com/S/LLY\">Lilly</a>(Eli Lilly)<span>LLY.N</span>Some of the savings from Zepbound and Foundayo due to price cuts.</p><p>According to Business Group on Health, a large employer policy research Group, about 10% of employers who currently provide coverage for GLP-1 drugs for weight loss say they plan to eliminate reimbursement for the drug in 2027.</p><p>Another survey conducted by benefits consulting firm Mercer showed that 5% of large employers, which the agency defines as businesses with more than 500 employees, plan to stop offering reimbursements for these drugs in 2027.</p><p>Mercer noted that 44% of businesses with more than 500 employees offer reimbursement for such drugs to people with obesity. Data from the Health Business Group shows that 67% of large employers offered reimbursement for GLP-1 drugs in 2026.</p><p>Reuters was the first to report this month that health insurer Cigna (<span>CI.N</span>) has ceased to reimburse employees for weight loss treatment expenses since July ((<span>link</span>)), and said that employees can purchase these drugs through other channels on their own.</p><p>New weight-loss tablets and injections from Novo and Lilly can now be purchased at a discounted price through the pharmaceutical company's official website, driven by an agreement with TrumpRx.gov, a Trump administration website.</p><p>Novo Nordisk launched its Wegovy diet pill in January, and Eli Lilly began selling its Foundayo diet pill in April, both starting at about $149 a month.</p><p>Many employers remain concerned that they won't get the same savings in agreements with pharmacy benefit managers, industry middlemen who negotiate drug prices for large businesses and health plans, as customers who buy outright and pay in cash, said Lauren Remspecher, director of the Health Purchasing Business Group.</p><p>\"One of the advantages of increased transparency in direct-to-consumer sales, as well as some government negotiated pricing, is that employers can now clearly see how much they are overpaying and where there is room for improvement,\" Remspecher said.</p><p>Oral drugs drive demand growth</p><p>Demand for these drugs has increased this year due to the oral launch, attracting patients who have never tried GLP-1 drugs before, which has led to high employer costs, according to five industry experts.</p><p>Many industry experts pointed out that compared with other treatment options, employers have found that patients have increased their long-term use of GLP-1 drugs, and the number of people eligible for medication is larger.</p><p>Studies show that the weight loss effects of Foundayo and Wegovy are 11% and 14%, respectively. Although they are lower than injectable drugs, they are more favored for patients who are afraid of injections.</p><p>\"Even though we're seeing a decrease in unit prices, the patient population continues to grow,\" said Luis Zollo, head of pharmacy practice at medical consulting firm Segal.</p><p>Aon, a welfare consultancy, has observed that injectable users are switching to oral versions, while patients who are new to GLP-1 also tend to opt for oral medications. Aon said it likewise expects insurance coverage for GLP-1 to shrink next year.</p><p><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Dan Mendelssohn, chief executive of Morgan Health, its Health care arm, said oral drugs are expected to reduce the cost of a single treatment this year.</p><p>\"But the market will grow every year,\" he said, \"and more and more people will take these drugs, so overall, this remains a major cost driver for employers.\"</p><p>(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. Reuters does not guarantee the accuracy of the automated translated text because the automated translation may be incorrect or fail to include the required context, and provides automated translation only for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","NVOH":"Novo Nordisk A/S B Shares ADRhedged","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","NVOX":"2倍做多NVO ETF-Defiance","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4534":"瑞士信贷持仓","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4516":"特朗普概念","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU2063271972.USD":"富兰克林创新领域基金","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","NVO":"诺和诺德","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4588":"碎股","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LLY":"礼来","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4599":"减肥药","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LLII":"REX LLY Growth & Income ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LLYX":"2倍做多LLY ETF-Defiance","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LLYZ":"2倍做空LLY ETF-Defiance","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","ELIL":"2倍做多LLY ETF-Direxion","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","ELIS":"1倍做空LLY ETF-Direxion","BK4007":"制药","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL4S42J0Q7:1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2642283463","content_text":"随着使用量的增加，部分美国雇主将于2027年停止报销GLP-1类减肥药Amina Niasse\n路透纽约6月11日 - 随着越来越多的人使用这些药物，部分雇主计划在2027年取消对GLP-1减肥药的保险覆盖，这抵消了诺和诺德（Novo Nordisk）旗下 NOVOb.CO 的Wegovy以及礼来（Eli Lilly）旗下 LLY.N 的Zepbound和Foundayo因降价带来的部分节省。据大型雇主政策研究组织“健康商业集团”（Business Group on Health）称，目前为减肥用GLP-1药物提供保险的雇主中，约有10%表示计划在2027年取消该药物报销。福利咨询公司美世（Mercer）进行的另一项调查显示，5%的大型雇主（该机构定义为雇员超过500人的企业）计划在2027年停止为这些药物提供报销。 美世指出，44%的员工人数超过500人的企业为肥胖症患者提供此类药物的报销。健康商业集团的数据显示，2026年67%的大型雇主为GLP-1药物提供报销。 路透本月率先报道称，健康保险公司Cigna（CI.N）已于7月起停止为员工报销减肥治疗费用（(link)），并表示员工可自行在其他渠道购买这些药物。  受与特朗普政府旗下网站TrumpRx.gov达成的协议推动，诺和诺德（Novo）和礼来（Lilly）的新型减肥药片及注射剂现可通过药企官网以折扣价购买。 诺和诺德于1月推出了Wegovy减肥药，礼来则于4月开始销售其Foundayo减肥药，两者的起价均为每月约149美元。 “健康采购商业集团”董事劳伦·雷姆斯佩彻表示，许多雇主仍担心，他们在与药房福利管理公司（即为大型企业和医疗计划谈判药价的行业中间商）达成的协议中，无法获得与直接购买并现金支付的客户同等的节省。 “直接面向消费者销售以及部分政府谈判定价的透明度提高，其优势之一在于，雇主现在能够清楚地看到自己多付了多少钱，以及哪里存在改进的空间，”雷姆斯佩彻说道。  口服药推动需求增长 据五位行业专家称，由于口服药物的推出，今年对这些药物的需求有所增加，吸引了此前从未尝试过GLP-1类药物的患者，这导致雇主成本居高不下。 多位行业专家指出，与其他治疗方案相比，雇主发现患者长期使用GLP-1类药物的情况增多，且符合用药条件的人群规模更大。  研究显示，Foundayo和Wegovy的减重效果分别为11%和14%，虽然低于注射型药物，但对于害怕打针的患者来说更受青睐。 “尽管我们看到单价有所下降，但患者群体仍在持续增长，”医疗咨询公司Segal的药学实践负责人路易斯·佐洛表示。   福利咨询公司怡安（Aon）观察到，注射剂用户正转向口服版本，同时新使用GLP-1的患者也倾向于选择口服药。怡安表示，该公司同样预计明年GLP-1的保险覆盖范围将缩减。  摩根大通旗下医疗保健部门摩根健康（Morgan Health）首席执行官丹·门德尔松表示，口服药有望在今年降低单次治疗的成本。 “但市场每年都会增长，”他说，“服用这些药物的人会越来越多，因此总体而言，这仍然是雇主的一项主要成本驱动因素。”(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","news_type":1,"symbols_score_info":{"ELIS":0.6,"LLY":1.92,"NVO":1.9,"NVOH":0.6,"LLYZ":0.6,"LLII":0.6,"LLYX":0.6,"NVOX":0.6,"ELIL":0.6}},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":574294825594880,"gmtCreate":1781217056359,"gmtModify":1781225490787,"author":{"id":"4183047379947902","authorId":"4183047379947902","name":"NayTy","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4183047379947902","authorIdStr":"4183047379947902"},"themes":[],"title":"","htmlText":"See","listText":"See","text":"See","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/574294825594880","repostId":"2642283463","repostType":2,"repost":{"id":"2642283463","kind":"highlight","weMediaInfo":{"introduction":"路透中文","home_visible":1,"media_name":"路透中文","id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1781172061,"share":"https://ttm.financial/m/news/2642283463?lang=en_US&edition=fundamental","pubTime":"2026-06-11 18:01","market":"us","language":"zh","title":"Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2642283463","media":"路透中文","summary":"福利咨询公司美世进行的另一项调查显示，5%的大型雇主计划在2027年停止为这些药物提供报销。健康商业集团的数据显示，2026年67%的大型雇主为GLP-1药物提供报销。多位行业专家指出，与其他治疗方案相比，雇主发现患者长期使用GLP-1类药物的情况增多，且符合用药条件的人群规模更大。怡安表示，该公司同样预计明年GLP-1的保险覆盖范围将缩减。","content":"<p><html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises</title></head><body>Amina Niasse</p><p><span>ReutersNEW YORK June 11</span><span>-</span>As more people use the drugs, some employers plan to eliminate insurance coverage for GLP-1 diet pills in 2027, which offsets Novo Nordisk's (<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>)<span>NOVOb.CO</span>Wegovy and<a href=\"https://laohu8.com/S/LLY\">Lilly</a>(Eli Lilly)<span>LLY.N</span>Some of the savings from Zepbound and Foundayo due to price cuts.</p><p>According to Business Group on Health, a large employer policy research Group, about 10% of employers who currently provide coverage for GLP-1 drugs for weight loss say they plan to eliminate reimbursement for the drug in 2027.</p><p>Another survey conducted by benefits consulting firm Mercer showed that 5% of large employers, which the agency defines as businesses with more than 500 employees, plan to stop offering reimbursements for these drugs in 2027.</p><p>Mercer noted that 44% of businesses with more than 500 employees offer reimbursement for such drugs to people with obesity. Data from the Health Business Group shows that 67% of large employers offered reimbursement for GLP-1 drugs in 2026.</p><p>Reuters was the first to report this month that health insurer Cigna (<span>CI.N</span>) has ceased to reimburse employees for weight loss treatment expenses since July ((<span>link</span>)), and said that employees can purchase these drugs through other channels on their own.</p><p>New weight-loss tablets and injections from Novo and Lilly can now be purchased at a discounted price through the pharmaceutical company's official website, driven by an agreement with TrumpRx.gov, a Trump administration website.</p><p>Novo Nordisk launched its Wegovy diet pill in January, and Eli Lilly began selling its Foundayo diet pill in April, both starting at about $149 a month.</p><p>Many employers remain concerned that they won't get the same savings in agreements with pharmacy benefit managers, industry middlemen who negotiate drug prices for large businesses and health plans, as customers who buy outright and pay in cash, said Lauren Remspecher, director of the Health Purchasing Business Group.</p><p>\"One of the advantages of increased transparency in direct-to-consumer sales, as well as some government negotiated pricing, is that employers can now clearly see how much they are overpaying and where there is room for improvement,\" Remspecher said.</p><p>Oral drugs drive demand growth</p><p>Demand for these drugs has increased this year due to the oral launch, attracting patients who have never tried GLP-1 drugs before, which has led to high employer costs, according to five industry experts.</p><p>Many industry experts pointed out that compared with other treatment options, employers have found that patients have increased their long-term use of GLP-1 drugs, and the number of people eligible for medication is larger.</p><p>Studies show that the weight loss effects of Foundayo and Wegovy are 11% and 14%, respectively. Although they are lower than injectable drugs, they are more favored for patients who are afraid of injections.</p><p>\"Even though we're seeing a decrease in unit prices, the patient population continues to grow,\" said Luis Zollo, head of pharmacy practice at medical consulting firm Segal.</p><p>Aon, a welfare consultancy, has observed that injectable users are switching to oral versions, while patients who are new to GLP-1 also tend to opt for oral medications. Aon said it likewise expects insurance coverage for GLP-1 to shrink next year.</p><p><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Dan Mendelssohn, chief executive of Morgan Health, its Health care arm, said oral drugs are expected to reduce the cost of a single treatment this year.</p><p>\"But the market will grow every year,\" he said, \"and more and more people will take these drugs, so overall, this remains a major cost driver for employers.\"</p><p>(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. Reuters does not guarantee the accuracy of the automated translated text because the automated translation may be incorrect or fail to include the required context, and provides automated translation only for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-06-11 18:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Some U.S. Employers to Stop Reimbursing GLP-1 Weight Loss Pills in 2027 as Use Rises</title></head><body>Amina Niasse</p><p><span>ReutersNEW YORK June 11</span><span>-</span>As more people use the drugs, some employers plan to eliminate insurance coverage for GLP-1 diet pills in 2027, which offsets Novo Nordisk's (<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>)<span>NOVOb.CO</span>Wegovy and<a href=\"https://laohu8.com/S/LLY\">Lilly</a>(Eli Lilly)<span>LLY.N</span>Some of the savings from Zepbound and Foundayo due to price cuts.</p><p>According to Business Group on Health, a large employer policy research Group, about 10% of employers who currently provide coverage for GLP-1 drugs for weight loss say they plan to eliminate reimbursement for the drug in 2027.</p><p>Another survey conducted by benefits consulting firm Mercer showed that 5% of large employers, which the agency defines as businesses with more than 500 employees, plan to stop offering reimbursements for these drugs in 2027.</p><p>Mercer noted that 44% of businesses with more than 500 employees offer reimbursement for such drugs to people with obesity. Data from the Health Business Group shows that 67% of large employers offered reimbursement for GLP-1 drugs in 2026.</p><p>Reuters was the first to report this month that health insurer Cigna (<span>CI.N</span>) has ceased to reimburse employees for weight loss treatment expenses since July ((<span>link</span>)), and said that employees can purchase these drugs through other channels on their own.</p><p>New weight-loss tablets and injections from Novo and Lilly can now be purchased at a discounted price through the pharmaceutical company's official website, driven by an agreement with TrumpRx.gov, a Trump administration website.</p><p>Novo Nordisk launched its Wegovy diet pill in January, and Eli Lilly began selling its Foundayo diet pill in April, both starting at about $149 a month.</p><p>Many employers remain concerned that they won't get the same savings in agreements with pharmacy benefit managers, industry middlemen who negotiate drug prices for large businesses and health plans, as customers who buy outright and pay in cash, said Lauren Remspecher, director of the Health Purchasing Business Group.</p><p>\"One of the advantages of increased transparency in direct-to-consumer sales, as well as some government negotiated pricing, is that employers can now clearly see how much they are overpaying and where there is room for improvement,\" Remspecher said.</p><p>Oral drugs drive demand growth</p><p>Demand for these drugs has increased this year due to the oral launch, attracting patients who have never tried GLP-1 drugs before, which has led to high employer costs, according to five industry experts.</p><p>Many industry experts pointed out that compared with other treatment options, employers have found that patients have increased their long-term use of GLP-1 drugs, and the number of people eligible for medication is larger.</p><p>Studies show that the weight loss effects of Foundayo and Wegovy are 11% and 14%, respectively. Although they are lower than injectable drugs, they are more favored for patients who are afraid of injections.</p><p>\"Even though we're seeing a decrease in unit prices, the patient population continues to grow,\" said Luis Zollo, head of pharmacy practice at medical consulting firm Segal.</p><p>Aon, a welfare consultancy, has observed that injectable users are switching to oral versions, while patients who are new to GLP-1 also tend to opt for oral medications. Aon said it likewise expects insurance coverage for GLP-1 to shrink next year.</p><p><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Dan Mendelssohn, chief executive of Morgan Health, its Health care arm, said oral drugs are expected to reduce the cost of a single treatment this year.</p><p>\"But the market will grow every year,\" he said, \"and more and more people will take these drugs, so overall, this remains a major cost driver for employers.\"</p><p>(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. Reuters does not guarantee the accuracy of the automated translated text because the automated translation may be incorrect or fail to include the required context, and provides automated translation only for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","NVOH":"Novo Nordisk A/S B Shares ADRhedged","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","NVOX":"2倍做多NVO ETF-Defiance","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4534":"瑞士信贷持仓","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4516":"特朗普概念","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU2063271972.USD":"富兰克林创新领域基金","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","NVO":"诺和诺德","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4588":"碎股","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LLY":"礼来","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4599":"减肥药","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LLII":"REX LLY Growth & Income ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LLYX":"2倍做多LLY ETF-Defiance","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LLYZ":"2倍做空LLY ETF-Defiance","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","ELIL":"2倍做多LLY ETF-Direxion","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","ELIS":"1倍做空LLY ETF-Direxion","BK4007":"制药","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL4S42J0Q7:1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2642283463","content_text":"随着使用量的增加，部分美国雇主将于2027年停止报销GLP-1类减肥药Amina Niasse\n路透纽约6月11日 - 随着越来越多的人使用这些药物，部分雇主计划在2027年取消对GLP-1减肥药的保险覆盖，这抵消了诺和诺德（Novo Nordisk）旗下 NOVOb.CO 的Wegovy以及礼来（Eli Lilly）旗下 LLY.N 的Zepbound和Foundayo因降价带来的部分节省。据大型雇主政策研究组织“健康商业集团”（Business Group on Health）称，目前为减肥用GLP-1药物提供保险的雇主中，约有10%表示计划在2027年取消该药物报销。福利咨询公司美世（Mercer）进行的另一项调查显示，5%的大型雇主（该机构定义为雇员超过500人的企业）计划在2027年停止为这些药物提供报销。 美世指出，44%的员工人数超过500人的企业为肥胖症患者提供此类药物的报销。健康商业集团的数据显示，2026年67%的大型雇主为GLP-1药物提供报销。 路透本月率先报道称，健康保险公司Cigna（CI.N）已于7月起停止为员工报销减肥治疗费用（(link)），并表示员工可自行在其他渠道购买这些药物。  受与特朗普政府旗下网站TrumpRx.gov达成的协议推动，诺和诺德（Novo）和礼来（Lilly）的新型减肥药片及注射剂现可通过药企官网以折扣价购买。 诺和诺德于1月推出了Wegovy减肥药，礼来则于4月开始销售其Foundayo减肥药，两者的起价均为每月约149美元。 “健康采购商业集团”董事劳伦·雷姆斯佩彻表示，许多雇主仍担心，他们在与药房福利管理公司（即为大型企业和医疗计划谈判药价的行业中间商）达成的协议中，无法获得与直接购买并现金支付的客户同等的节省。 “直接面向消费者销售以及部分政府谈判定价的透明度提高，其优势之一在于，雇主现在能够清楚地看到自己多付了多少钱，以及哪里存在改进的空间，”雷姆斯佩彻说道。  口服药推动需求增长 据五位行业专家称，由于口服药物的推出，今年对这些药物的需求有所增加，吸引了此前从未尝试过GLP-1类药物的患者，这导致雇主成本居高不下。 多位行业专家指出，与其他治疗方案相比，雇主发现患者长期使用GLP-1类药物的情况增多，且符合用药条件的人群规模更大。  研究显示，Foundayo和Wegovy的减重效果分别为11%和14%，虽然低于注射型药物，但对于害怕打针的患者来说更受青睐。 “尽管我们看到单价有所下降，但患者群体仍在持续增长，”医疗咨询公司Segal的药学实践负责人路易斯·佐洛表示。   福利咨询公司怡安（Aon）观察到，注射剂用户正转向口服版本，同时新使用GLP-1的患者也倾向于选择口服药。怡安表示，该公司同样预计明年GLP-1的保险覆盖范围将缩减。  摩根大通旗下医疗保健部门摩根健康（Morgan Health）首席执行官丹·门德尔松表示，口服药有望在今年降低单次治疗的成本。 “但市场每年都会增长，”他说，“服用这些药物的人会越来越多，因此总体而言，这仍然是雇主的一项主要成本驱动因素。”(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","news_type":1,"symbols_score_info":{"ELIS":0.6,"LLY":1.92,"NVO":1.9,"NVOH":0.6,"LLYZ":0.6,"LLII":0.6,"LLYX":0.6,"NVOX":0.6,"ELIL":0.6}},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}